Skip to search formSkip to main contentSkip to account menu

mirabegron

Known as: 2-(2-Aminothiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl] Acetamide, 4-Thiazoleacetamide, 2-Amino-N-(4-(2-(((2R)-2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)-, Betmiga 
An orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), with muscle relaxing, neuroprotective and potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

9 relations
24 HR mirabegron 50 MG Extended Release Oral Tablet [Myrbetriq]Decreased Bladder Contractility [PE]NCIt Antineoplastic Agent Terminology

Broader (3)

AcetanilidesThiazolesUrological Agents

Narrower (3)

BetanisMyrbetriqYM 178

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Mirabegron induces relaxant effects via cAMP signaling‐dependent and ‐independent pathways in detrusor smooth muscle
We previously found that mirabegron exerts a relaxant effect in the presence of the β3‐adrenoceptor antagonist SR58894A during… 
2019
2019
Urodynamics as a Prognosticator of Mirabegron Treatment Outcomes
Aims: To determine if findings at urodynamics prognosticate improvements in overactive bladder symptoms among women receiving… 
Review
2018
Review
2018
Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis
PurposeMirabegron, a β3-adrenoceptor agonist, was approved for overactive bladder (OAB), but worsened hypertension was a… 
2017
2017
Bladder telemetry: A new approach to evaluate micturition behavior under physiological and inflammatory conditions
To establish a new approach to cystometry using telemetry in conscious rats and to use this technique to determine the role of… 
2014
2014
ICH E14‐Compatible Holter Bin Method and its Equivalence to Individual Heart Rate Correction in the Assessment of Drug‐Induced QT Changes
The Holter bin method evaluates QT interval changes in the presence of heart rate changes without correcting the QT interval… 
2013
2013
Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys
Mirabegron is a novel β3-adrenoceptor agonist developed for the treatment of overactive bladder. To clarify the relationship… 
2012
2012
Effect of mirabegron, a novel β3-adrenoceptor agonist, on bladder function during storage phase in rats
Mirabegron, a selective β3-adrenoceptor agonist, facilitates urine storage function by exerting a relaxing effect on bladder… 
2012
2012
MODULATION OF NON‐VOIDING ACTIVITY BY THE MUSCARINERGIC ANTAGONIST TOLTERODINE AND THE β3‐ADRENOCEPTOR AGONIST MIRABEGRON IN CONSCIOUS RATS WITH PARTIAL OUTFLOW OBSTRUCTION
Interest is growing in the NVA of the bladder wall in animals and humans and the link is made, among others, with bladder… 
2012
2012
COMPARISON OF THE EFFECTS OF MIRABEGRON, A NOVEL BETA3-ADRENOCEPTOR AGONIST, WITH THE ANTICHOLINERGIC AGENT, OXYBUTININ, ON PRIMARY BLADDER AFFERENT ACTIVITY AND BLADDER MICROCONTRACTIONS IN RATS
Hypothesis / aims of study Mirabegron, which has been approved in Japan, is the first β3-adrenoceptor (β3-AR) agonist for the… 
2012
2012
Age-related efficacy of the selective ß3-adrenoceptor agonist mirabegron for the treatment of overactive bladder (OAB): pooled analysis of three prospective, randomised Phase III studies in patients…
1. St Mary’s Hospital, Imperial College, Urogynaecology Department, London, UK, 2. Infanta Leonor Hospital, Department of Urology… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)